Patents by Inventor Robert M. Scarborough

Robert M. Scarborough has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-[1H]-quinolone and 2-[1H]-quinoxalone inhibitors of factor Xa
    Publication number: 20020058657
    Abstract: Novel compounds of general formula I: 1
    Type: Application
    Filed: February 1, 2001
    Publication date: May 16, 2002
    Inventors: Bing-Yan Zhu, Robert M. Scarborough
  • Isoquinolone inhibitors of factor Xa
    Publication number: 20020058677
    Abstract: Novel compounds of formula I: 1
    Type: Application
    Filed: March 26, 2001
    Publication date: May 16, 2002
    Inventors: Charles K. Marlowe, Wenhao Li, Ting Su, Robert M. Scarborough
  • Oxindole inhibitors of factor Xa
    Publication number: 20020052368
    Abstract: Novel compounds of formula I: 1
    Type: Application
    Filed: March 26, 2001
    Publication date: May 2, 2002
    Inventors: Charles K. Marlowe, Kim A. Kane-Maguire, Bing-Yan Zhu, Robert M. Scarborough
  • Benzamides and related inhibitors of factor Xa
    Patent number: 6376515
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: April 23, 2002
    Assignee: COR Therapeutics, Inc.
    Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick A. Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert M. Scarborough
  • Selective factor Xa inhibitors
    Patent number: 6369063
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: April 13, 1998
    Date of Patent: April 9, 2002
    Assignee: Cor Therapeutics, Inc.
    Inventors: Ting Su, Bing-Yan Zhu, Robert M. Scarborough
  • Selective factor Xa inhibitors
    Patent number: 6369080
    Abstract: Novel compounds of formula I: including its pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.
    Type: Grant
    Filed: October 10, 1997
    Date of Patent: April 9, 2002
    Assignee: COR Therapeutics, Inc.
    Inventors: Bing-Yan Zhu, Robert M. Scarborough
  • Platelet ADP receptor inhibitors
    Publication number: 20020025961
    Abstract: Novel compounds of formula (I) to (VI), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I)-(VI), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 5, 2001
    Publication date: February 28, 2002
    Inventors: Robert M. Scarborough, Hans-Michael Jantzen, Wolin Huang, David M. Sedlock, Charles Marlowe
  • Bicyclic sulfonyl amino inhibitors of factor Xa
    Publication number: 20020019394
    Abstract: Novel compounds of formulae I or Ia: 1
    Type: Application
    Filed: March 26, 2001
    Publication date: February 14, 2002
    Inventors: Wenhao Li, Charles K. Marlowe, Robert M. Scarborough
  • Indalone and benzimidazolone inhibitors of factor Xa
    Publication number: 20020019395
    Abstract: Novel compounds of general formula I: 1
    Type: Application
    Filed: February 1, 2001
    Publication date: February 14, 2002
    Inventors: Bing-Yan Zhu, Robert M. Scarborough
  • Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Publication number: 20020013325
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Application
    Filed: July 6, 2001
    Publication date: January 31, 2002
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Kenneth J. Ruterbories, Michael Paal, Gerd Ruhter, Theo Schotten, Wolfgang Stenzel, Robert M. Scarborough
  • 3,4-dihydro-2H-benzo[1,4]oxazine inhibitors of factor Xa
    Publication number: 20020013314
    Abstract: Novel compounds of formula I: 1
    Type: Application
    Filed: February 1, 2001
    Publication date: January 31, 2002
    Inventors: Bing-Yan Zhu, Robert M. Scarborough
  • Integrin antagonists
    Publication number: 20010034369
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian integrins are disclosed. The compounds are useful in vitro or in vivo for preventing or treating thrombotic or restenotic disorders.
    Type: Application
    Filed: May 15, 2001
    Publication date: October 25, 2001
    Inventors: Robert M. Scarborough, Mark Smyth, Ting Su, Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffry Bernard Franciskovich
  • Nucleic acids encoding the C140 receptor
    Patent number: 6297026
    Abstract: Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are useful in an assay for detecting a substance which affects C140 receptor activity, either receptor agonists or antagonists. Further, the elucidation of the structure of the C140 receptor permits the design of agonist and antagonist compounds which are useful in such assays. The availability of the C140 receptor also permits production of antibodies specifically immunoreactive with one or more antigenic epitopes of the C140 receptor.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 2, 2001
    Assignee: Cor Therapeutics Inc.
    Inventors: Johan Sundelin, Robert M. Scarborough
  • Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Patent number: 6291469
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, as shown by formula (I): wherein Q, L, Ai, Bj, R0, R3, R10, m, n, p and q are as defined in the disclosure, which are useful in inhibiting of platelet aggregation.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: September 18, 2001
    Assignees: Eli Lilly and Company, COR Therapeutics Inc.
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Kenneth J. Ruterbories, Michael Paal, Gerd Ruhter, Robert M. Scarborough, Theo Schotten, Wolfgang Stenzel
  • SELECTIVE FACTOR XA INHIBITORS
    Publication number: 20010020033
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Application
    Filed: October 10, 1997
    Publication date: September 6, 2001
    Inventors: BING-YAN ZHU, ROBERT M. SCARBOROUGH
  • Selective factor Xa inhibitors
    Patent number: 6262047
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: October 10, 1997
    Date of Patent: July 17, 2001
    Assignee: COR Therapeutics, Inc.
    Inventors: Bing-Yan Zhu, Robert M. Scarborough
  • Inhibitors of factor Xa
    Patent number: 6245743
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: May 15, 1998
    Date of Patent: June 12, 2001
    Assignee: COR Therapeutics, Inc.
    Inventors: Charles K. Marlowe, Robert M. Scarborough, Alan M. Laibelman, Uma Sinha, Bing-Yan Zhu
  • Integrin antagonists
    Patent number: 6245809
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian integrins are disclosed. The compounds are useful in vitro or in vivo for preventing or treating thrombotic or restenotic disorders.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: June 12, 2001
    Assignees: Cor Therapeutics Inc., Eli Lilly & Company
    Inventors: Robert M. Scarborough, Mark Smyth, Ting Su, Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffry Bernard Franciskovich
  • Selective factor Xa inhibitors
    Patent number: 6211183
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: April 13, 1998
    Date of Patent: April 3, 2001
    Assignee: COR Therapeutics, Inc.
    Inventors: Charles K. Marlowe, Bing-Yan Zhu, Robert M. Scarborough
  • Ketoheterocyclic inhibitors of factor Xa
    Patent number: 6211154
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 3, 2001
    Assignee: COR Therapeutics, Inc.
    Inventors: Robert M. Scarborough, Charles K. Marlowe, Bing-Yan Zhu